Health
TurtleTree Announces Strategic Partnership with Strive, a Sustainable Nutrition Company; Expands Consumer Product Offerings with LF+™ for Adult and Sports Nutrition
Strive and TurtleTree to Collaborate on a Immunity Support Beverage for Adults
and a Protein Powder to be Made Available to the Public Q1 2025
SACRAMENTO, Calif. and SINGAPORE, June 26, 2024 /PRNewswire/ -- TurtleTree
2024-06-26 21:01
3152
CARING PHARMACY UNVEILS MOM & CUTIE PRODUCT LINE IN CELEBRATORY 30TH ANNIVERSARY EVENT
KUALA LUMPUR, Malaysia, June 26, 2024 /PRNewswire/ -- CARiNG Pharmacy proudly celebrates its 30th anniversary with the grand launch of their 'Mom and Cutie' product line. To commemorate this milestone event, CARiNG Pharmacy held a Health & Beauty Carnival at 1 Utama Shopping Centre, Ground Floor ...
2024-06-26 20:49
2136
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimburse...
2024-06-26 16:44
3747
Apollo Cancer Centres Collaborates With Accuray to Launch India Sub- Continent's First Robotic Stereotactic Radiotherapy Program
* The program will enhance the development of oncology care, thereby, advancing healthcare landscape of the region * Participants will engage in in-depth discussions and demonstrations, ensuring a robust and practical learning experience BANGALORE, India, June 26, 2024 /PRNewswire/ -- Apollo...
2024-06-26 13:53
1966
Yoshihiro Yoneda Appointed President of the International Human Frontier Science Program Organization
STRASBOURG, France, June 26, 2024 /PRNewswire/ -- The International Human Frontier Science Program Organization (HFSPO) is pleased to announce that acclaimed Japanese cell biologist and international research leaderYoshihiro Yoneda will assume the role of President for the global life science or...
2024-06-26 08:00
1725
AXA Introduces New TotalAssure Critical Illness Series
Prioritises pre-emptive care for three early risk conditions with continuous support throughout the health journey Study reveals that nearly 90% of Hong Kong residents are not fully aware of their health conditions, putting them at higher risk of critical illness as early disease signs go undete...
2024-06-25 22:21
2250
Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes
Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an ove...
2024-06-25 20:22
1557
Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression
MORRISVILLE, N.C., June 25, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, is proud to announce the receipt of a prestigious gr...
2024-06-25 19:57
1311
CLL Community Urges Hospital Authority to List Next-Generation BTK Inhibitor on Drug Formulary to Bring Hope and Improve Quality of Life for CLL Patients
HONG KONG, June 25, 2024 /PRNewswire/ -- Chronic Lymphocytic Leukaemia ('CLL') is a lymphoproliferative disease characterised by the abnormal proliferation of lymphocytes. The progression of CLL is relatively slow and it is a mild haematological malignancy. Cypress Charitable Trust is aHong Kong ...
2024-06-25 17:00
1919
IBISA raises $3 million to scale parametric insurance solutions, strengthening climate resilience across Asia and Africa.
LUXEMBOURG, June 25, 2024 /PRNewswire/ -- IBISA
2024-06-25 13:00
1902
Singclean: Unveiled Singfiller® and Singderm® in IMCAS ASIA 2024, Poised for Thailand's Big Launch
BANGKOK, June 25, 2024 /PRNewswire/ -- Singclean, a global player and a leading Chinese manufacturer of high-quality medical aesthetic products, was excited to announce in IMCAS Asia that Singfiller® and Singderm® HA fillers will launch in Thailand this November. Although still not officially cer...
2024-06-25 11:00
2196
Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
2024-06-25 08:17
2245
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024
SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
2024-06-25 08:00
2377
NABR Commends the IUCN's Decision to Reassess the Status of Long-Tailed Macaques
A Science-Based Approach Will Determine if the Species is Truly 'Endangered' WASHINGTON, June 25, 2024 /PRNewswire/ -- The National Association for Biomedical Research (NABR) commends the Union for the Conservation of Nature (IUCN)'s decision to reassess the 'Endangered' designation of long-taile...
2024-06-25 05:32
1749
AXA Celebrates Record-Breaking 10 Industry Wins at Bloomberg Businessweek Financial Institutions Awards 2024
HONG KONG, June 24, 2024 /PRNewswire/ -- AXA Hong Kong and Macau ("AXA") set a record at the Bloomberg Businessweek Financial Institutions Awards 2024, winning a total of ten prestigious awards. This remarkable achievement includes six Excellence awards and four Outstanding awards, covering vario...
2024-06-24 12:08
1983
Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa
SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling...
2024-06-24 09:00
1785
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
ROCKVILLE, Md. and SUZHOU, China, June 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of Amer...
2024-06-24 08:15
3142
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
BEIJING and BRIDGEWATER, N.J., June 23, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in...
2024-06-23 21:09
2984
Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference
* A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekl...
2024-06-22 07:00
5141
Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer
CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indicated as monotherapy for the treatment of patients with post-transplant l...
2024-06-21 19:28
2375
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
